Skip to main content
SpringerLink
Log in

Langetermijnuitkomsten na hydrocortisonbehandeling voor chronische longziekte bij prematuur geboren kinderen

  • Artikelen
  • Published:
Tijdschrift voor Kindergeneeskunde

Samenvatting

Het gebruik van postnatale corticosteroïden voor de preventie of behandeling van chronische longziekte bij pasgeborenen blijft een punt van discussie. Dexamethason kent vele negatieve bijwerkingen. Hydrocortison zou een alternatief kunnen zijn indien het even effectief is en minder nadelige effecten op de lange termijn veroorzaakt. Dit artikel geeft een overzicht van de tot nu toe gepubliceerde studies betreffende de behandeling met hydrocortison in de neonatale periode in relatie tot de langetermijnuitkomsten op de neuromotorische ontwikkeling.

Summary

The use of postnatal corticosteroids to prevent or treat chronic lung disease in newborns remains a controversial issue. Dexamethasone has many negative side effects. Hydrocortisone could be a suitable alternative if equally effective and causing fewer negative sequelae on neuromotor development. This paper describes the published studies on hydrocortisone treatment in the neonatal period in relation with long-term neurodevelopmental outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatuur

  1. Committee on Obstetric Practice. ACOG committee opinion: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol. 2002;99(5 Pt 1):871-3.

    Google Scholar 

  2. Barrington KJ. Hazards of systemic steroids for ventilator-dependent preterm infants: what would a parent want? CMAJ 2001;165(1):33-4.

  3. Thebaud B, Lacaze-Masmonteil T, Watterberg K. Postnatal glucocorticoids in very preterm infants: `the good, the bad, and the ugly'? Pediatrics. 2001;107:413-5.

  4. Finer NN, Craft A, Vaucher YE, et al. Postnatal steroids: short-term gain, long-term pain? J Pediatr. 2000;137:9-13.

    Google Scholar 

  5. Jobe AH. Postnatal corticosteroids for preterm infants – do what we say, not what we do. N Engl J Med. 2004;350:1349-51.

    Google Scholar 

  6. Shinwell ES. Current dilemmas in postnatal steroid therapy for chronic lung disease in preterm infants. Biol Neonate. 2003;84:96-100.

    Google Scholar 

  7. Mammel MC, Green TP, Johnson DE, Thompson TR. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet. 1983;1:1356-8.

    Google Scholar 

  8. Hack M, Fanaroff AA. Outcomes of children of extremely low birthweight and gestational age in the 1990's. Early Hum Dev. 1999;53:193-218.

    Google Scholar 

  9. Yeh TF, Lin YJ, Huang CC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics. 1998;101:E7.

    Google Scholar 

  10. O'Shea TM, Kothadia JM, Klinepeter KL, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics. 1999;104(1 Pt 1):15-21.

    Google Scholar 

  11. Shinwell ES, Karplus M, Bader D, et al. Neonatologists are using much less dexamethasone. Arch Dis Child Fetal Neonatal Ed. 2003;88:F432-3.

    Google Scholar 

  12. Committee on Fetus and Newborn. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics. 2002;109: 330-8.

    Google Scholar 

  13. Finer NN, Powers RJ, Ou CH, et al. Prospective evaluation of postnatal steroid administration: a 1-year experience from the California Perinatal Quality Care Collaborative. Pediatrics. 2006;117: 704-13.

    Google Scholar 

  14. Short EJ, Klein NK, Lewis BA, et al. Cognitive and academic consequences of bronchopulmonary dysplasia and very low birth weight: 8-year-old outcomes. Pediatrics. 2003;112:e359.

    Google Scholar 

  15. Yeh TF, Lin YJ, Lin HC, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med. 2004;350:1304-13.

    Google Scholar 

  16. Parikh NA, Lasky RE, Kennedy KA, et al. Postnatal dexamethasone therapy and cerebral tissue volumes in extremely low birth weight infants. Pediatrics. 2007;119:265-72.

    Google Scholar 

  17. Baden M, Bauer CR, Colle E, et al. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics. 1972; 50:526-34.

    Google Scholar 

  18. Watterberg KL, Gerdes JS, Gifford KL, Lin HM. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics. 1999;104:1258-63.

    Google Scholar 

  19. Watterberg KL, Scott SM. Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia. Pediatrics. 1995;95:120-5.

    Google Scholar 

  20. Heide-Jalving M van der, Kamphuis PJ, Laan MJ van der, et al. Short- and long-term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone? Acta Paediatr. 2003;92:827-35.

    Google Scholar 

  21. Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics. 2004;114:1649-57.

    Google Scholar 

  22. Peltoniemi O, Kari MA, Heinonen K, et al. Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. J Pediatr. 2005;146:632-7.

    Google Scholar 

  23. Bonsante F, Latorre G, Iacobelli S, et al. Early low-dose hydrocortisone in very preterm infants: a randomized, placebo-controlled trial. Neonatology. 2007;91:217-21.

    Google Scholar 

  24. Taeusch HW Jr, Wang NS, Baden N, et al. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome: II. Pathology. Pediatrics. 1973;52:850-4.

    Google Scholar 

  25. Watterberg KL, Shaffer ML, Mishefske MJ, et al. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics. 2007; 120:40-8.

    Google Scholar 

  26. Lodygensky GA, Rademaker K, Zimine S, et al. Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics. 2005;116:1-7.

    Google Scholar 

  27. Rademaker KJ, Rijpert M, Uiterwaal CS, et al. Neonatal hydrocortisone treatment related to 1H-MRS of the hippocampus and short-term memory at school age in preterm born children. Pediatr Res. 2006;59:309-13.

    Google Scholar 

  28. Rademaker KJ, Uiterwaal CS, Groenendaal F, et al. Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children. J Pediatr. 2007;150:351-7.

    Google Scholar 

  29. Karemaker R, Heijnen CJ, Veen S, et al. Differences in behavioral outcome and motor development at school age after neonatal treatment for chronic lung disease with dexamethasone versus hydrocortisone. Pediatr Res. 2006;60:745-50.

    Google Scholar 

  30. Kloet ER de, Vreugdenhil E, Oitzl MS, Joels M. Brain corticosteroid receptor balance in health and disease. Endocr Rev. 1998;19:269-301.

    Google Scholar 

  31. Sapolsky RM, Uno H, Rebert CS, Finch CE. Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosci. 1990;10:2897-902.

    Google Scholar 

  32. Uno H, Tarara R, Else JG, et al. Hippocampal damage associated with prolonged and fatal stress in primates. J Neurosci. 1989;9:1705-11.

    Google Scholar 

  33. Huang CC, Lin HR, Liang YC, Hsu KS. Effects of neonatal corticosteroid treatment on hippocampal synaptic function. Pediatr Res. 2007;62:267-70.

    Google Scholar 

  34. Almeida OF, Conde GL, Crochemore C, et al. Subtle shifts in the ratio between pro- and antiapoptotic molecules after activation of corticosteroid receptors decide neuronal fate. FASEB J. 2000;14:779-90.

    Google Scholar 

  35. Holmes MC, Seckl JR. The role of 11beta-hydroxysteroid dehydrogenases in the brain. Mol Cell Endocrinol. 2006;248:9-14.

    Google Scholar 

  36. Holmes MC, Sangra M, French KL, et al. 11beta-hydroxysteroid dehydrogenase type 2 protects the neonatal cerebellum from deleterious effects of glucocorticoids. Neuroscience. 2006;137:865-73.

    Google Scholar 

  37. Taketomo CK, Hodding JH, Kraus D (eds.). Pediatric dosage handbook, 11th ed. Lexicomp, 2004.

  38. Reist M, Marshall KA, Jenner P, Halliwell B. Toxic effects of sulphite in combination with peroxynitrite on neuronal cells. J Neurochem. 1998;71: 2431-8.

    Google Scholar 

  39. Baud O, Laudenbach V, Evrard P, Gressens P. Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives. Pediatr Res. 2001;50:706-11.

    Google Scholar 

  40. Caeymaex L, Gatel P, Castel C, et al. Low-dose hydrocortisone alone does not lead to gastro-intestinal perforation in ELBW infants. SPR, 2006.

  41. Hallman M, Peltoniemi O, Saarela T. Early neonatal hydrocortisone: study rather than treat. Pediatrics. 2006;118:2540-2.

    Google Scholar 

  42. Ramanathan R, Siassi B, Sardesai S, deLemos R. Dexamethasone versus hydrocortisone for hypotension refractory to high dose inotropic agents and incidence of candida infection in extremely low birth weight infants. Pediatr Res. 2006;39: 240.

    Google Scholar 

  43. Botas CM, Kurlat I, Young SM, Sola A. Disseminated candidal infections and intravenous hydrocortisone in preterm infants. Pediatrics. 1995;95: 883-7.

    Google Scholar 

  44. Ng PC, Lee CH, Bnur FL, et al. A double-blind, randomized, controlled study of a `stress dose' of hydrocortisone for rescue treatment of refractory hypotension in preterm infants. Pediatrics. 2006; 117:367-75.

    Google Scholar 

  45. Eichenwald EC, Stark AR. Are postnatal steroids ever justified to treat severe bronchopulmonary dysplasia? Arch Dis Child Fetal Neonatal Ed. 2007;92:F334-7.

  46. Doyle LW, Davis PG, Morley CJ, et al. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics. 2006;117:75-83

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. www.bsl.nl/shop/tydschrift-vkindergeneeskunde-0376-7442.html

    K. J. Rademaker

Authors
  1. K. J. Rademaker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Groenendaal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. S. de Vries
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. van Bel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. J. Rademaker.

Additional information

Mw. dr. K.J. Rademaker, dhr. dr. F. Groenendaal, mw. prof. dr. L.S. de Vries, dhr. prof. dr. F. van Bel, afdeling Neonatologie, Wilhelmina Kinderziekenhuis, UMC Utrecht.

Correspondentieadres: Mw. K.J. Rademaker, afdeling Neonatologie. KE 04.123.1, Wilhelmina Kinderziekenhuis UMC Utrecht, Postbus 85090, 3508 AB Utrecht

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rademaker, K.J., Groenendaal, F., de Vries, L.S. et al. Langetermijnuitkomsten na hydrocortisonbehandeling voor chronische longziekte bij prematuur geboren kinderen. KIND 76, 242–249 (2008). https://doi.org/10.1007/BF03078212

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03078212

Search

Navigation